We are certified researchers committed to excellence.

COPD STUDIES

Since COPD is progressive, it is important to identify and treat patients at early stages in order to prevent further deterioration. Combination inhalers such as Breztri and Trelegy and improved breathlessness and reduced exacerbation.  Biologics will play a significant role in controlling the disease and potentially reverse the disease. Through clinical trials we now see Dupixent or dupilumab reducing exacerbation and increase lung function an additional 94 ml. Other biologics that block IL-5R, TSLP, OX-40L and IL-33 may help control inflammation of COPD.
We are actively recruiting in several biologics in COPD.
Anti-IL-33 related therapy was just shown at American Thoracic Society to reduce exacerbation by as much as 40-70%. We will start the next stage to closely evaluate this improvement in more details. We will explore the mechanism in which this therapy will alter the lung injury to allow better functional healing.
To find out more contact us.

COVID19 studies

The purpose of the studies is to determine whether a new treatment or vaccine works and is safe for people to use.  Over the last three of years of the pandemic we learned that people over the age of 65 and immunosuppresssd or compromised people develop more severe disease. As the covid19 virus has mutated, it has rendered majority if not most of the monovalent vaccine and monoclonal therapy ineffective and removed from the FDA Emergency authorization. Evusheld has been effective in helping those immune compromised individuals (link to times magazine article) Supernova trial is a new version of Evusheld against covid19. This monoclonal antibody binds to the most conserved portion of the S Spike protein. It has been tested  and can neutralize the older variants as well as the current variants in the system.

ASTHMA STUDIES

Asthma is a chronic inflammatory disease that causes airway inflammation and airway remodeling or scaring. Clinical research helps us understand how the disease is caused, how it develops and how it is best treated. Stopping the inflammation and slowing the progression of remodeling will be the key in treating this disease. Like COPD, several different biologics may play a role in blocking the inflammation and help reverse the disease. Take the disease into your own hands and learn more how to control this disease. Contact us for more information on how to participate.

Phase 2 trial of Itepekimab show reduction of COPD exacerbation or worsening by as much as 40-70%. We will initiate Phase 3 trial in June 2023. Will also look at the mechanistic changes within the lung to explore its beneficial effects.

Osteoarthritis studies

Osteoarthritis is a type of degenerative joint disease that results from breakdown of joint cartilage and underlying bone which affects 1 in 7 adults in the United States. The most common symptoms are joint pain and stiffness progress slowly over years. Other symptoms may include joint swelling, decreased range of motion, and, when the back is affected, weakness or numbness of the arms and legs.

PRP or platelet-rich-plasma has helped improve joints but is currently not approved by the FDA or covered by insurance companies for knee osteoarthritis. A typical injection can cost $700-1,000 per dose.